Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: Future directions

Keyphrases

• Cardiovascular Disease 100%
• Pharmacological Inhibitors 100%
• Poly(ADP-ribose) Polymerase 100%
• PARP Inhibitor (PARPi) 100%
• Reactive Oxygen Species 25%
• Human Disease 25%
• Clinical Trials 25%
• Life-threatening 25%
• Inflammatory Cells 25%
• Therapeutic Effect 25%
• Clinical High Risk 25%
• Cell Injury 25%
• Severe Disease 25%
• Experimental Therapeutics 25%
• Inflammatory Diseases 25%
• DNA Double-strand Breaks 25%
• Organ Damage 25%
• Reactive Nitrogen Species 25%
• Ischemia-reperfusion Injury 25%
• Myocardial Infarction 25%
• Cardiopulmonary Bypass 25%
• Thoracic Aortic Surgery 25%
• Clinical Development 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 100%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 100%
• Cardiovascular Disease 100%
• Disease 50%
• Clinical Trial 25%
• Reactive Oxygen Metabolite 25%
• Ischemia 25%
• Therapeutic Effect 25%
• Inflammatory Disease 25%
• Organ Injury 25%
• Reactive Nitrogen Species 25%
• Heart Infarction 25%
• Single Stranded DNA 25%
• Aneurysm 25%
• Cerebrovascular Accident 25%